Definium Therapeutics, Inc. (DFTX) dividends
DFTX on Nasdaq, Health Care
Sign in to get an email when it declares a dividend.
Definium Therapeutics, Inc. dividend: key facts
Own Definium Therapeutics, Inc.? See exactly what it will pay you
Add your shares to a free DiviCompass portfolio to see your next DFTX dividend in your own money, every payment month by month, and an email when it declares. Free for up to 10 holdings, no card needed.
Price history
End-of-day closes on Nasdaq in USD. Dots mark ex-dividend dates.
Dividend history
Declared dividends. Special dividends are marked and excluded from yield and forecasts.
Reported financials
Annual figures from filings, converted to units.
Results, reports and dividend announcements
About Definium Therapeutics, Inc.
Definium Therapeutics, Inc., formerly known as MindMed, is a New York-based biotechnology company that is currently developing clinical and therapeutic applications for psychedelic and, more broadly, psychoplastogenic drugs.
From Wikipedia, CC BY-SA 4.0.
Next 12 months
No dividends expected from the data available.
Estimate confidence: None
Company news
- Psychedelic: Definium Therapeutics narrows quarterly net loss12 Nov 2026 · TheFly
In this weekâs âPsychedelic,â The Flyâs recurring series focused on psychedelic stock news, The Fly looks back on earnings, a NDA submission and a psilocybin shipment. EARNINGS: On Monday, Definiumâ¦
- Definium Therapeutics reports Q3 EPS (46c), consensus (56c)10 Nov 2026 · TheFly
âOur positive Phase 3 topline results from Voyage and Panorama this quarter further strengthened the evidence supporting DT120 ODT. Together with our previously reported results, these findings demons...
- Definium Therapeutics price target raised to $70 from $66 at RBC Capital10 Nov 2026 · TheFly
RBC Capital raised the firmâs price target on Definium Therapeutics (DFTX) to $70 from $66 and keeps an Outperform rating on the shares after its Q3 results. Regulatory updates areâ¦
- Definium Therapeutics Reports Third Quarter 2026 Financial Results and Recent Highlights10 Nov 2026 · Business Wire
NEW YORK--(BUSINESS WIRE)-- #GAD--Definium Therapeutics, Inc. (âDefiniumâ or the âCompanyâ) (NASDAQ: DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics ...
- Definium Therapeutics Announces New Employee Inducement Grants9 Nov 2026 · Business Wire
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (âDefiniumâ or the âCompanyâ), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address un...
- Definium Therapeutics presents Phase 3 data for DT120 ODT at NEI Fall Congress4 Nov 2026 · TheFly
Definium Therapeutics (DFTX) announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO.T opline results from Panorama, the Companyâs s...
- Definium Therapeutics Presents Topline Phase 3 Data for DT120 ODT in Generalized Anxiety Disorder and Major Depressive Disorder at 2026 NEI Fall Congress4 Nov 2026 · Business Wire
NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (âDefiniumâ or the âCompanyâ), a late-stage clinical biopharmaceutical company developing a new generation of th...
- Definium Therapeutics to Participate at Upcoming Investor Conferences3 Nov 2026 · Business Wire
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Insufficient verified data for a financial-health score
Dividend data and price last updated 18 Nov 2026.